Yoshida, T., Kamimura, K., Hosaka, K., Doumori, K., Oka, H., Sato, A., Fukuhara, Y., Watanabe, S., Sato, T., Yoshikawa, A., Tomidokoro, T. and Terai, S. (2019) Colorectal Neuroendocrine Carcinoma: A Case Report and Review of the Literature. World Journal of Clinical Cases, 7, 1865-1875.
https://doi.org/10.12998/wjcc.v7.i14.1865

has been cited by the following article:

• TITLE: A Huge Metastatic Liver of a Neuroendocrin Tumor Explored by SPECT/CT with 99mTc-Tektrotyd: A Case Report

  AUTHORS: Imad Ghfir, Manal Otmani, Chaimae Bensaid, Majdouline Bellakhdar, Malika Çaoui, Nouzha BenRaïs

  KEYWORDS: Colonic Neuroendocrine Tumor, Liver Metastases, Bone Metastases, SPECT/CT, 99mTc-Tektrotyd

  JOURNAL NAME: Open Journal of Medical Imaging, Vol.13 No.3, August 16, 2023

  ABSTRACT: Background: Colorectal neuroendocrine tumors are rare and have a heterogeneous clinical representation and variable prognosis. High grade neuroendocrine tumors (NETs) are characterized by destructive and aggressive growth, followed by rapid spread. For this purpose, SPECT/CT with 99mTc-Tektrotyd is very useful for imaging and staging of NETs. Case Report: A 50-year-old man with a huge metastatic liver from an unknown neuroendocrine tumor (NET). SPECT/CT with 99mTc-Tektrotyd was performed in this patient, it showed a huge metastatic hepatomegaly compressing neighboring organs with bone metastases, and also revealed the primary colon tumor. Discussion and Conclusion: In recent decades, the incidence and prevalence of neuroendocrine tumors (NETs), especially those of the colorectal segments, have been increasing. 99mTc-EDDA/HYNIC-TOC (Tektrotyd?) was introduced into the market and its use has been approved for scintigraphic imaging of patients with NETs and other SSTR-positive tumors. It provides in vivo metabolic data related to the over-expression of Somatostatin Receptors (SSTRs) and also predicts response to peptide receptor radionuclide therapy (PRRT).